These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 29514803)

  • 1. Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study.
    Cohen SB; Alonso-Ruiz A; Klimiuk PA; Lee EC; Peter N; Sonderegger I; Assudani D
    Ann Rheum Dis; 2018 Jun; 77(6):914-921. PubMed ID: 29514803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis.
    Jani RH; Gupta R; Bhatia G; Rathi G; Ashok Kumar P; Sharma R; Kumar U; Gauri LA; Jadhav P; Bartakke G; Haridas V; Jain D; Mendiratta SK
    Int J Rheum Dis; 2016 Nov; 19(11):1157-1168. PubMed ID: 26176644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study.
    Cohen S; Genovese MC; Choy E; Perez-Ruiz F; Matsumoto A; Pavelka K; Pablos JL; Rizzo W; Hrycaj P; Zhang N; Shergy W; Kaur P
    Ann Rheum Dis; 2017 Oct; 76(10):1679-1687. PubMed ID: 28584187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active rheumatoid arthritis.
    Jamshidi A; Gharibdoost F; Vojdanian M; Soroosh SG; Soroush M; Ahmadzadeh A; Nazarinia MA; Mousavi M; Karimzadeh H; Shakibi MR; Rezaieyazdi Z; Sahebari M; Hajiabbasi A; Ebrahimi AA; Mahjourian N; Rashti AM
    Arthritis Res Ther; 2017 Jul; 19(1):168. PubMed ID: 28728599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension.
    Genovese MC; Glover J; Greenwald M; Porawska W; El Khouri EC; Dokoupilova E; Vargas JI; Stanislavchuk M; Kellner H; Baranova E; Matsunaga N; Alten R
    Arthritis Res Ther; 2019 Dec; 21(1):281. PubMed ID: 31831079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis.
    Fleischmann RM; Alten R; Pileckyte M; Lobello K; Hua SY; Cronenberger C; Alvarez D; Bock AE; Sewell KL
    Arthritis Res Ther; 2018 Aug; 20(1):178. PubMed ID: 30111357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety, immunogenicity and efficacy comparing FKB327 with the adalimumab reference product in patients with active rheumatoid arthritis: data from randomised double-blind and open-label extension studies.
    Genovese MC; Kellner H; Arai Y; Muniz R; Alten R
    RMD Open; 2020 Apr; 6(1):. PubMed ID: 32371430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term safety, efficacy, and immunogenicity of adalimumab biosimilar BI 695501 and adalimumab reference product in patients with moderately-to-severely active rheumatoid arthritis: results from a phase 3b extension study (VOLTAIRE-RAext).
    Cohen SB; Czeloth N; Lee E; Klimiuk PA; Peter N; Jayadeva G
    Expert Opin Biol Ther; 2019 Oct; 19(10):1097-1105. PubMed ID: 31387417
    [No Abstract]   [Full Text] [Related]  

  • 9. Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-PK) in healthy subjects.
    Wynne C; Altendorfer M; Sonderegger I; Gheyle L; Ellis-Pegler R; Buschke S; Lang B; Assudani D; Athalye S; Czeloth N
    Expert Opin Investig Drugs; 2016 Dec; 25(12):1361-1370. PubMed ID: 27813422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis.
    Weinblatt ME; Baranauskaite A; Niebrzydowski J; Dokoupilova E; Zielinska A; Jaworski J; Racewicz A; Pileckyte M; Jedrychowicz-Rosiak K; Cheong SY; Ghil J
    Arthritis Rheumatol; 2018 Jan; 70(1):40-48. PubMed ID: 28950421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial.
    Hanauer S; Liedert B; Balser S; Brockstedt E; Moschetti V; Schreiber S
    Lancet Gastroenterol Hepatol; 2021 Oct; 6(10):816-825. PubMed ID: 34388360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52-92 data from a randomized, double-blind, phase 3 trial.
    Fleischmann RM; Alvarez DF; Bock AE; Cronenberger C; Vranic I; Zhang W; Alten R
    Arthritis Res Ther; 2021 Sep; 23(1):248. PubMed ID: 34563243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study.
    Smolen JS; Choe JY; Prodanovic N; Niebrzydowski J; Staykov I; Dokoupilova E; Baranauskaite A; Yatsyshyn R; Mekic M; Porawska W; Ciferska H; Jedrychowicz-Rosiak K; Zielinska A; Lee Y; Rho YH
    Ann Rheum Dis; 2018 Feb; 77(2):234-240. PubMed ID: 29042358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54.
    Alten R; Batko B; Hala T; Kameda H; Radominski SC; Tseluyko V; Babic G; Cronenberger C; Hackley S; Rehman M; von Richter O; Zhang M; Cohen S
    RMD Open; 2019; 5(1):e000876. PubMed ID: 30997153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy.
    Choe JY; Prodanovic N; Niebrzydowski J; Staykov I; Dokoupilova E; Baranauskaite A; Yatsyshyn R; Mekic M; Porawska W; Ciferska H; Jedrychowicz-Rosiak K; Zielinska A; Choi J; Rho YH; Smolen JS
    Ann Rheum Dis; 2017 Jan; 76(1):58-64. PubMed ID: 26318384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty-Two-Week Phase III Randomized Study Results.
    Weinblatt ME; Baranauskaite A; Dokoupilova E; Zielinska A; Jaworski J; Racewicz A; Pileckyte M; Jedrychowicz-Rosiak K; Baek I; Ghil J
    Arthritis Rheumatol; 2018 Jun; 70(6):832-840. PubMed ID: 29439289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis.
    Cohen S; Pablos JL; Pavelka K; Müller GA; Matsumoto A; Kivitz A; Wang H; Krishnan E
    Arthritis Res Ther; 2019 Mar; 21(1):84. PubMed ID: 30922373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plain language summary of the VOLTAIRE-RA in patients with moderate-to-severe rheumatoid arthritis.
    Cohen SB; Lee EC
    Immunotherapy; 2022 Oct; 14(15):1183-1190. PubMed ID: 36065786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis.
    Edwards CJ; Monnet J; Ullmann M; Vlachos P; Chyrok V; Ghori V
    Clin Rheumatol; 2019 Dec; 38(12):3381-3390. PubMed ID: 31396834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects.
    Hillson J; Mant T; Rosano M; Huntenburg C; Alai-Safar M; Darne S; Palmer D; Pavlova BG; Doralt J; Reeve R; Goel N; Weilert D; Rhyne PW; Chance K; Caminis J; Roach J; Ganguly T
    Pharmacol Res Perspect; 2018 Feb; 6(1):. PubMed ID: 29417761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.